Overview

A Study of LY2881835 in Healthy People and People With Diabetes

Status:
Completed
Trial end date:
2011-08-17
Target enrollment:
Participant gender:
Summary
This will be the first study in which LY2881835 is given to humans in order to evaluate the safety and any side effects of LY2881835 in humans as well as how long LY2881835 stays in the body and its effect on blood sugar levels. The study consists of two parts. In part A, healthy subjects will participate and in part B, patients with type 2 Diabetes Mellitus (T2DM) will participate.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company